Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from BioPharmaDive

13:47 EST 24th November 2017 | BioPortfolio

Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.

More Information about BioPharmaDive on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.

Showing News Articles 1–25 of 1,000+ from BioPharmaDive

Wednesday 22nd November 2017

J&J eyes broader market for blood cancer med Darzalex

New study results could support approval of Darzalex in combination with three other drugs as a first-line treatment for certain patients with multiple myeloma.

Concordia faces fine for bad pricing behavior

A U.K. regulator accused the drugmaker of price gouging, citing a near-6,000% increase in the price of a generic thyroid drug over 10 years.

AmerisourceBergen hands over another $625M for manufacturing violations

The latest settlement comes just two months after the drug distributor agreed to pay $260 million in connection with criminal charges for its subsidiary's pre-filled syringe program.

GSK boosted by US approval of two-drug HIV pill

Combining Tivicay with J&J's Edurant, the new regimen offers patients a less burdensome treatment option than current combos of three or more drugs. 

AMR Centre launches, announces new antimicrobial agreement

The launch of the AMR Centre at Alderley Park in the UK aims to fill the gap between basic research and the market for new antimicrobials.

Tuesday 21st November 2017

Optum gets caught up in Express Scripts, Anthem legal fight

The latest legal challenge pulls Optum into an ongoing battle that adds turmoil to a rapidly changing and consolidating space.   

Novo Nordisk: Obesity should be considered a chronic disease

Shifting dynamics in the diabetes market are pushing the Danish drugmaker to pursue other therapeutic areas. 

FDA pushes for more abuse-deterrent opioid generics

Under new Commissioner Gottlieb, the FDA has been looking to increase competition across markets by ushering more drugs through the system more efficiently. 

Cytokinetics to discontinue ALS drug after Phase 3 miss

The California biotech will now turn to an earlier clinical candidate, which it hopes could prove more effective in treating the neurodegenerative disease.

Ardelyx scraps late-stage drug in another pipeline setback

The move leaves Ardelyx's pipeline with a single Phase 3 candidate that has faced trouble in the clinic and skepticism among investors.

Thursday 26th October 2017

Medicines Co. cuts staff to fund PCSK9 studies

In an effort to put more resources behind clinical development of inclisiran, the drugmaker will take its headcount down to below 60 people.

Amgen faces conundrum as biosimilars both help and hurt

The biotech is counting on biosimilars to help grow topline revenue, just as competition from the copycat biologics cuts into its biggest blockbusters. 

Vertex grows CF franchise as combos move forward

The outlook for Vertex is bright, as positive data from experimental combination treatments could eventually position the biotech to reach 90% of cystic fibrosis patients.

Slow Otezla growth dampens Celgene's long-term prospects

With stateside sales of the anti-inflammation drug relatively flat, the big biotech lowered its 2020 guidance — and then saw its stock plummet.

Wednesday 25th October 2017

FDA hands PTC its latest rejection

After a disastrous advisory committee meeting and a refusal-to-file letter, the regulatory agency has handed down another rejection for the DMD drug.  

Sanofi debuts brand campaign to play up role as health partner

Using the new corporate signature "Empowering Life," the French drugmaker seeks to unify its five business around a central message. 

Incyte pays $150M to bolster combo strategy

Through a deal with MacroGenics, Incyte is adding a second checkpoint inhibitor to its pipeline to test in combination with its slate of immunotherapies.

AbbVie taps Alector for deeper dive into Alzheimer's

As research into the immune system booms, the two companies will investigate treatments that aim to use the body's defenses to fight neurodegenerative disorders.

With Advair copies looming, GSK keeps focus on new drugs

Recent approvals of Trelegy Ellipta and Shingrix should help bolster the drugmaker's prospects in key areas as it prepares for a generic hit. 

Mixed results in NASH for Gilead

While the higher dose showed a clinical effect, GS-0976 didn't hit the mark at its lowest dose, and the study missed its additional endpoints.

Smarter data integration yields better patient outcomes

New data integration tools can help make personalized medicine a reality — revolutionizing the treatment of cancer and other notoriously complex diseases. 

Reader poll: Pfizer most likely buyer for Spark

When asked what company would be most interested in the gene therapy drugmaker, BioPharma Dive readers had mixed feelings, but Pfizer won out. 

Tuesday 24th October 2017

Expanded label opens new market for Alexion's Soliris

The FDA has now approved the blockbuster drug as a treatment for patients with generalized myasthenia gravis, an uncommon neruomuscular disorder.

Biogen doubling down on aducanumab

The big biotech is paying $150 million to reclaim 15% of the Alzheimer's candidate's potential royalties, and may take the agreement one step further.

Eyes on Alcon as Novartis notches modest growth

Analysts are focused on the possible divestiture of the eye care business, while Novartis' newer drugs help make up for competition to Gleevec. 


Quick Search
Advertisement
 

News Quicklinks